Literature DB >> 15455606

Is second-line anti-tuberculosis drug susceptibility testing reliable?

S J Kim, M A Espinal, C Abe, G H Bai, F Boulahbal, L Fattorin, C Gilpin, S Hoffner, K M Kam, N Martin-Casabona, L Rigouts, V Vincent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15455606

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  14 in total

1.  GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples.

Authors:  A Lacoma; N García-Sierra; C Prat; J Maldonado; J Ruiz-Manzano; L Haba; P Gavin; S Samper; V Ausina; J Domínguez
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

Review 2.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system.

Authors:  Fernanda Maruri; Timothy R Sterling; Anne W Kaiga; Amondrea Blackman; Yuri F van der Heijden; Claudine Mayer; Emmanuelle Cambau; Alexandra Aubry
Journal:  J Antimicrob Chemother       Date:  2012-01-25       Impact factor: 5.790

3.  Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Malcolm D Yates; Francis A Drobniewski
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 4.  Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs.

Authors:  David J Horne; Lancelot M Pinto; Matthew Arentz; S-Y Grace Lin; Edward Desmond; Laura L Flores; Karen R Steingart; Jessica Minion
Journal:  J Clin Microbiol       Date:  2012-11-14       Impact factor: 5.948

5.  Drug-resistant tuberculosis: what are the treatment options?

Authors:  Amr S Albanna; Dick Menzies
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

6.  Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.

Authors:  P Juréen; K Angeby; E Sturegård; E Chryssanthou; C G Giske; J Werngren; M Nordvall; A Johansson; G Kahlmeter; S Hoffner; T Schön
Journal:  J Clin Microbiol       Date:  2010-03-17       Impact factor: 5.948

7.  Performance of the MTBDRsl assay in Georgia.

Authors:  N Tukvadze; N Bablishvili; R Apsindzelashvili; H M Blumberg; R R Kempker
Journal:  Int J Tuberc Lung Dis       Date:  2014-02       Impact factor: 2.373

8.  Rapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual mycobacterium growth indicator tube system.

Authors:  Anandi Martin; Andrea von Groll; Krista Fissette; Juan Carlos Palomino; Francis Varaine; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2008-10-22       Impact factor: 5.948

9.  Worldwide emergence of extensively drug-resistant tuberculosis.

Authors:  N Sarita Shah; Abigail Wright; Gill-Han Bai; Lucia Barrera; Fadila Boulahbal; Nuria Martín-Casabona; Francis Drobniewski; Chris Gilpin; Marta Havelková; Rosario Lepe; Richard Lumb; Beverly Metchock; Françoise Portaels; Maria Filomena Rodrigues; Sabine Rüsch-Gerdes; Armand Van Deun; Veronique Vincent; Kayla Laserson; Charles Wells; J Peter Cegielski
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

10.  Extensively drug-resistant Mycobacterium tuberculosis, India.

Authors:  Rajesh Mondal; Amita Jain
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.